Bausch Health Companies Q3 2026 Earnings Call Transcript
Bausch Health Companies reported strong third-quarter results, exceeding $1 billion in quarterly adjusted EBITDA for the first time and marking 14 consecutive quarters of growth. The company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted cash flow, driven by strong performance in Salix, International, and Solta Medical segments. Management also discussed debt reduction efforts, capital allocation, and future strategic priorities, including pipeline development and operational excellence, while acknowledging anticipated Q4 headwinds related to Xifaxan.
Put this headline into context
Use TradingAgents AI to connect the story to the company's filings, fundamentals, market structure, competing bull and bear arguments, and risk review.
Headlines and excerpts belong to the original publisher. Ticker associations are informational and may be incomplete. Market news is not personalized financial advice.